|
E updated label can be found on the company website (www.GSK.com under Products). In the Precautions section of the new label, GSK cites clinical trial data confirming the existence of several withdrawal symptoms, including abnormal dreams, paresthesia abnormal sensations , and dizziness. According to the label, since the marketing of Paxil, other withdrawal symptoms have been reported in association with the discontinuation of the drug. These post-marketing reports include "dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), agitation, anxiety, nausea and sweating." However, the company claims that the reactions reported since the start of marketing "may have no causal relationship to the drug" and are "generally self-limiting." Dr. Breggin stressed the importance of the "anxiety" and "agitation" mentioned in the label as reported in association with Paxil withdrawal. He observed that anxiety and agitation can contribute to aggressive, violent or suicidal behavior. Aggressive behavior is especially likely to result when a drug causes or increases agitation and anxiety in individuals already suffering from psychiatric disorders such as anxiety, depression, panic, stress, and obsessions or compulsions. Dr. Breggin also stated that there is a growing body of clinical and research literature demonstrating irritability and aggression during withdrawal from Paxil. However, the updated label makes no mention of any danger of aggressive, violent or suicidal behavior during Paxil withdrawal. Dr. Breggin was gratified to see the company update its
| Paxil and alcohol | Paxil medication | Off paxil | Side effects from paxil | Paxil and wellbutrin | Paxil overdose | Stopping paxil | [ Phentermine ]
|
